Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
104.51 USD | +0.44% | -0.35% | -4.81% |
Nov. 15 | NeuroOne Medical Technologies Names Christopher Volker as Chief Operating Officer | MT |
Nov. 13 | Wall Street wavers after rally, focus on inflation data | RE |
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
- diagnostic systems and instruments (38%);
- vascular devices (21%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (17.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (11.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (12.7%).
Net sales are distributed geographically as follows: the United States (41.5%), Germany (5.4%), China (4.9%), Japan (4.4%), India (3.8%), Switzerland (3.1%), Canada (2.9%) and other (34%).
Calendar
2024-01-23
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
BUY
Number of Analysts
24
Last Close Price
104.51USD
Average target price
116.25USD
Spread / Average Target
+11.24%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.81% | 181 B $ | |
+2.10% | 106 B $ | |
-8.65% | 67 062 M $ | |
+3.29% | 45 194 M $ | |
+31.40% | 40 450 M $ | |
+21.75% | 40 151 M $ | |
+45.42% | 25 322 M $ | |
-8.00% | 24 513 M $ | |
+26.05% | 24 288 M $ | |
+29.78% | 23 854 M $ |
- Stock
- Equities
- Stock Abbott Laboratories - Nyse
- News Abbott Laboratories
- Earnings Flash (ABT) ABBOTT Posts Q1 EPS $1.03, vs. Street Est of $0.98